Update on Topical Treatments for Psoriasis: The Role of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam

被引:8
作者
Puig, L. [1 ]
Carretero, G. [2 ]
机构
[1] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Dermatol, Barcelona, Spain
[2] Hosp Univ Gran Canaria Dr Negrin, Dept Dermatol, Las Palmas Gran Canaria, Spain
来源
ACTAS DERMO-SIFILIOGRAFICAS | 2019年 / 110卷 / 02期
关键词
Psoriasis; Topical treatment; Calcipotriol; Betamethasone dipropionate; Aerosol foam; PLAQUE PSORIASIS; SUPERIOR EFFICACY; FORMULATION; VULGARIS; MANAGEMENT; SAFETY; PANEL; VS;
D O I
10.1016/j.ad.2018.05.010
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Topical agents are the first-line treatment for mild and moderate psoriasis, but factors such as frequency of administration, organoleptic properties, and the limited short term results can reduce treatment adherence and effectiveness. Innovations in topical treatments are linked not only to the discovery of new molecules, but also to the reformulation of existing active ingredients based on improvements to administration, organoleptic properties, bioavailability, and ease of use. Calcipotriol and betamethasone dipropionate aerosol foam is a new formulation in which the active ingredients are dissolved in a mixture of volatile propellants that evaporate quickly, leaving a supersaturated solution of calcipotriol and betamethasone dipropionate that enhances penetration into the epidermis. In this article, we take a look at the new calcipotriol and betamethasone dipropionate aerosol formulation and briefly review the main evidence supporting the use of topical treatments for psoriasis. (c) 2018 AEDV. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:115 / 123
页数:9
相关论文
共 50 条
  • [31] Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation
    Gallo, L.
    Megna, M.
    Cirillo, T.
    Caterino, P.
    Lodi, G.
    Mozzillo, R.
    Dente, V
    Balato, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (07) : 1312 - 1315
  • [32] Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
    Adam, David N.
    Bernasconi, Marie Y. Jablonski
    Thoning, Henrik
    Wu, Jashin J.
    DERMATOLOGY AND THERAPY, 2022, 12 (11) : 2589 - 2600
  • [33] Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease
    Pink, A. E.
    Jalili, A.
    Berg, P.
    Calzavara-Pinton, P. G.
    de la Cueva Dobao, P.
    Thaci, D.
    Torpet, M.
    Jensen, K. L.
    Segaert, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (06) : 1116 - 1123
  • [34] Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data
    Megna, Matteo
    Cinelli, Eleonora
    Camela, Elisa
    Fabbrocini, Gabriella
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (06) : 599 - 620
  • [35] Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis
    Amat-Samaranch, Victoria
    Puig, Lluis
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (04) : 423 - 432
  • [36] The DESIRE study - psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice
    Clareus, Birgitta Wilson
    Houwing, Ronald
    Sindrup, Jens H.
    Wigchert, Suzanne
    EUROPEAN JOURNAL OF DERMATOLOGY, 2009, 19 (06) : 581 - 585
  • [37] Systematic review and practical guidance on the use of topical calcipotriol and topical calcipotriol with betamethasone dipropionate as long-term therapy for mild-to-moderate plaque psoriasis
    Zhao, Yi
    Asahina, Akihiko
    Asawanonda, Pravit
    Frez, Ma. Lorna
    Imafuku, Shinichi
    Hyun Kim, Dong
    Theng, Colin
    Wang, Liangchun
    Zhang, Jiang An
    Zimmo, Sameer
    JOURNAL OF DERMATOLOGY, 2021, 48 (07) : 940 - 960
  • [38] Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis
    Kin, Kevin C.
    Hill, Dane
    Feldman, Steven R.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (06) : 789 - 797
  • [39] Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study
    Paul, C.
    Gold, L. Stein
    Cambazard, F.
    Kalb, R. E.
    Lowson, D.
    Bang, B.
    Griffiths, C. E. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 119 - 126
  • [40] Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris
    Queille-Roussel, C.
    Nielsen, J.
    Lacour, J. -P.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (06) : 529 - 533